Senator Criticizes Genentech

A U.S. senator said Genentech’s plan to restrict availability of Avastin so doctors might be forced to use the more expensive medicine Lucentis to treat an eye disease will cost taxpayers $1 billion to $ 3 billion annually.
Inside Bay Area